CARVEDILOL PLUS NUCS TO PREVENT THE PROGRESSION OF ESOPHAGEAL VARICES IN VIROLOGICAL SUPPRESSED HBV-CIRRHOSIS PATIENTS: A RANDOMISED, OPEN-LABEL TRIAL

被引：0

作者：

Wang, Bingqiong ^{[1
]}

Zhou, Jialing ^{[1
]}

Wu, Xiaoning ^{[2
]}

Sun, Yameng ^{[2
]}

Li, Lei ^{[3
]}

Li, Ping ^{[4
]}

Li, Minghui ^{[5
]}

Jiang, Wei ^{[6
]}

Xu, Mingyi ^{[7
]}

Feng, Bo ^{[8
]}

Xu, Xiaoyuan ^{[9
]}

Cheng, Jilin ^{[10
]}

Xie, Wen ^{[11
]}

Han, Tao ^{[12
]}

Wang, Xiaozhong ^{[13
]}

Li, Hai ^{[14
]}

Piao, Hongxin ^{[15
]}

Zhao, Xinyu ^{[16
,17
,18
]}

Chen, Shuyan ^{[5
]}

Meng, Tongtong ^{[2
]}

Guan, Qiushuang ^{[1
]}

Meng, Fandong ^{[19
]}

Kong, Yuanyuan ^{[20
,21
]}

Ou, Xiaojuan ^{[2
]}

Jia, Jidong ^{[2
]}

You, Hong ^{[5
]}

机构：

[1] Capital Med Univ, Beijing Key Lab Translat Med Liver Cirrhosis, Natl Clin Res Ctr Digest Dis, Liver Res Ctr,Beijing Friendship Hosp, Beijing, Peoples R China

[2] Capital Med Univ, Beijing Friendship Hosp, Natl Clin Res Ctr Digest Dis, Liver Res Ctr, Beijing, Peoples R China

[3] Capital Med Univ, Beijing Youan Hosp, Dept Gastroenterol & Hepatol, Beijing, Peoples R China

[4] Tianjin Second Peoples Hosp, Dept Hepatol, Tianjin, Peoples R China

[5] Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Beijing, Peoples R China

[6] Fudan Univ, Dept Gastroenterol, Zhongshan Hosp Xiamen, Xiamen 361015, Peoples R China

[7] Shanghai Jiao Tong Univ, Sch Med, Dept Gastroenterol & Hepatol, Shanghai Gen Hosp, Shanghai, Peoples R China

[8] Peking Univ, Peoples Hosp, Beijing, Peoples R China

[9] Peking Univ First Hosp, Beijing, Peoples R China

[10] Shanghai Publ Hlth Clin Ctr, Dept Gastroenterol, Shanghai, Peoples R China

[11] Capital Med Univ, Beijing Ditan Hosp, Ctr Liver Dis, Beijing, Peoples R China

[12] Tianjin Med Univ, Dept Hepatol, Tianjin Cent Hosp 3, Tianjin, Peoples R China

[13] Xinjiang Med Univ, Xinjiang Hosp Tradit Chinese Med, Affiliated Hosp 4, Urumqi, Xinjiang, Peoples R China

[14] Tianjin Xiqing Hosp, Dept Gastroenterol, Tianjin, Peoples R China

[15] Yanbian Univ, Dept Infect Dis, Affiliated Hosp, Yanji, Jilin, Peoples R China

[16] Natl Clin Res Ctr Digest Dis, Dept Clin Epidemiol, Beijing, Peoples R China

[17] Natl Clin Res Ctr Digest Dis, EBM Unit, Beijing, Peoples R China

[18] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China

[19] Capital Med Univ, Beijing Friendship Hosp, Natl Clin Res Ctr Digest Dis, Dept Gastroenterol, Beijing, Peoples R China

[20] Capital Med Univ, Beijing Friendship Hosp, Beijing Clin Res Inst, Clin Epidemiol, Beijing, Peoples R China

[21] Capital Med Univ, Beijing Friendship Hosp, Beijing Clin Res Inst, EBM Unit, Beijing, Peoples R China

来源：

HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

206

引用

页码：S217 / S218

页数：2

共 50 条

[31] Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Cremolini, Chiara
Antoniotti, Carlotta
Rossini, Daniele
Lonardi, Sara
Loupakis, Fotios
Pietrantonio, Filippo
Bordonaro, Roberto
Latiano, Tiziana Pia
Tamburini, Emiliano
Santini, Daniele
Passardi, Alessandro
Marmorino, Federica
Grande, Roberta
Aprile, Giuseppe
Zaniboni, Alberto
Murgioni, Sabina
Granetto, Cristina
Buonadonna, Angela
Moretto, Roberto
Corallo, Salvatore
Cordio, Stefano
Antonuzzo, Lorenzo
Tomasello, Gianluca
Masi, Gianluca
Ronzoni, Monica
Di Donato, Samantha
Carlomagno, Chiara
Clavarezza, Matteo
Ritorto, Giuliana
Mambrini, Andrea
Roselli, Mario
Cupini, Samanta
Mammoliti, Serafina
Fenocchio, Elisabetta
Corgna, Enrichetta
Zagonel, Vittorina
Fontanini, Gabriella
Ugolini, Clara
Boni, Luca
Falcone, Alfredo
LANCET ONCOLOGY, 2020, 21 (04): : 497 - 507
[32] Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial
Zhang, Lihui
Zhang, Yunliang
Shen, Sheng'ai
Wang, Xueying
Dong, Luling
Li, Qiuyun
Ren, Weidong
Li, Yufeng
Bai, Jianling
Gong, Qiuhong
Kuang, Hongyu
Qi, Lin
Lu, Qiang
Cheng, Wenli
Liu, Yanjie
Yan, Shuang
Wu, Donghong
Fang, Hui
Hou, Fang
Wang, Yingju
Yang, Zhixia
Lian, Xu
Du, Jianling
Sun, Ningling
Ji, Linong
Li, Guangwei
LANCET DIABETES & ENDOCRINOLOGY, 2023, 11 (08): : 567 - 577
[33] The diabetes community exercise programme plus usual care versus usual care in patients with type 2 diabetes: A randomised, two-arm, parallel, open-label trial
Hale, L.
Higgs, C.
Gray, A. R.
Mann, J.
Mani, R.
Sullivan, T.
Terry, J.
Keen, D.
Stokes, T.
ECLINICALMEDICINE, 2022, 46
[34] Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
Galle, Peter R.
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Zhu, Andrew X.
Kim, Tae-You
Kudo, Masatoshi
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed
Li, Daneng
Mulla, Sohail
Verret, Wendy
Xu, Derek-Zhen
Hernandez, Sairy
Ding, Beiying
Liu, Juan
Huang, Chen
Lim, Ho Yeong
Cheng, Ann-Lii
Ducreux, Michel
LANCET ONCOLOGY, 2021, 22 (07): : 991 - 1001
[35] Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial
Bonvolot, Sylvie
Gronchi, Alessandro
Le Pechoux, Cecile
Swallow, Carol J.
Strauss, Dirk
Meeus, Pierre
van Coevorden, Frits
Stoldt, Stephan
Stoeckle, Eberhard
Rutkowski, Piotr
Rastrelli, Marco
Rout, Chandrajit P.
Hompes, Daphne
De Paoli, Antonino
Sangalli, Claudia
Honore, Charles
Chung, Peter
Miah, Aisha
Blay, Jean Yves
Fiore, Marco
Stelmes, Jean-Jacques
Dei Tos, Angelo P.
Baldini, Elizabeth H.
Litiere, Saskia
Marreaud, Sandrine
Gelderblom, Hans
Haas, Rick L.
LANCET ONCOLOGY, 2020, 21 (10): : 1366 - 1377
[36] Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
Manns, Michael
Samuel, Didier
Gane, Edward J.
Mutimer, David
McCaughan, Geoff
Buti, Maria
Prieto, Martin
Luis Calleja, Jose
Peck-Radosavljevic, Markus
Mullhaupt, Beat
Agarwal, Kosh
Angus, Peter
Yoshida, Eric M.
Colombo, Massimo
Rizzetto, Mario
Dvory-Sobol, Hadas
Denning, Jill
Arterburn, Sarah
Pang, Phillip S.
Brainard, Diana
McHutchison, John G.
Dufour, Jean-Francois
Van Vlierberghe, Hans
van Hoek, Bart
Forns, Xavier
LANCET INFECTIOUS DISEASES, 2016, 16 (06): : 685 - 697
[37] Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Dummer, Reinhard
Ascierto, Paolo A.
Gogas, Helen J.
Arance, Ana
Mandala, Mario
Liszkay, Gabriella
Garbe, Claus
Schadendorf, Dirk
Krajsova, Ivana
Gutzmer, Ralf
Sileni, Vanna Chiarion
Dutriaux, Caroline
de Groot, Jan Willem B.
Yamazaki, Naoya
Loquai, Carmen
Moutouh-de Parseval, Laure A.
Pickard, Michael D.
Sandor, Victor
Roberti, Caroline
Flaherty, Keith T.
LANCET ONCOLOGY, 2018, 19 (10): : 1315 - 1327
[38] Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial
Rosellini, Matteo
Tassinari, Elisa
Marchetti, Andrea
Mollica, Veronica
Massari, Francesco
EUROPEAN UROLOGY, 2024, 85 (01) : 97 - 98
[39] Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)
Aoyagi, Reiko
Hamada, Hiromichi
Sato, Yasunori
Suzuki, Hiroyuki
Onouchi, Yoshihiro
Ebata, Ryota
Nagashima, Kengo
Terauchi, Moe
Terai, Masaru
Hanaoka, Hideki
Hata, Akira
BMJ OPEN, 2015, 5 (12):
[40] Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial
Amiot, Aurelien
Seksik, Philippe
Meyer, Antoine
Stefanescu, Carmen
Wils, Pauline
Altwegg, Romain
Vuitton, Lucine
Plastaras, Laurianne
Nicolau, Adrien
Pereira, Bruno
Duveau, Nicoals
Laharie, David
Mboup, Bassirou
Boualit, Medina
Allez, Matthieu
Rajca, Sylvie
Chanteloup, Elise
Bouguen, Guillaume
Bazin, Thomas
Goutorbe, Felix
Richard, Nicolas
Moussata, Driffa
Vicaut, Eric
Peyrin-Biroulet, Laurent
GUT, 2024,

← 1 2 3 4 5 →